The experience with oxaliplatin in the treatment of upper gastrointestinal carcinomas

Seminars in Oncology

Volumn 30, Issue 4 SUPPL. 15, 2003, Pages 54-61

  Hoff, Paulo Marcelo G ^a   Fuchs, Charles S ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CARBOPLATIN; CISPLATIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; METHOTREXATE; OXALIPLATIN; PLATINUM DERIVATIVE;

ADVANCED CANCER; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COLD EXPOSURE; COLORECTAL CANCER; CONFERENCE PAPER; DEHYDRATION; DIARRHEA; DRUG EFFICACY; DRUG INFUSION; ESOPHAGITIS; ESOPHAGUS CARCINOMA; FEBRILE NEUTROPENIA; GASTROINTESTINAL CARCINOMA; HUMAN; INFECTION; MUCOSA INFLAMMATION; NAUSEA; NEPHROTOXICITY; NEUROPATHY; OTOTOXICITY; PANCREAS CANCER; PRIORITY JOURNAL; SENSORY NEUROPATHY; STOMACH CARCINOMA; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

EID: 0142063360     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0093-7754(03)00406-8     Document Type: Conference Paper

References (36)

1. Misset JL, Bleiberg H, Sutherland W, et al: Oxaliplatin clinical activity: A review. Crit Rev Oncol Hematol 35:75-93, 2000
2. Extra JM, Marty M, Brienza S, et al: Pharmacokinetics and safety profile of oxaliplatin. Semin Oncol 25:13-22, 1998
3. Cassidy J, Misset JL: Oxaliplatin-related side effects: characteristics and management. Semin Oncol 29:11-20, 2002
4. Royce ME, Hoff PM, Pazdur R: Progress in colorectal cancer chemotherapy: How far have we come, how far to go? Drugs Aging 17:201-216, 2000
5. de Gramont A, Figer A, Seymour M, et al: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938-2947, 2000
6. MacDonald JS: Oxaliplatin: New opportunities for the treatment of gastrointestinal cancer. Cancer Invest 20:287-289, 2002
7. Greenlee RT, Murray T, Bolden S, et al: Cancer statistics, 2000. CA Cancer J Clin 50:7-33, 2000
8. Daly JM, Karnell LH, Menck HR: National Cancer Data Base report on esophageal carcinoma. Cancer 78:1820-1828, 1996
9. Coia LR, Minsky BD, John MJ, et al: The evaluation and treatment of patients receiving radiation therapy for carcinoma of the esophagus: Results of the 1992-1994 Patterns of Care Study. Cancer 85:2499-2505, 1999
10. Kelsen DP, Ginsberg R, Pajak TF, et al: Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 339:1979-1984, 1998
11. Medical Research Council Oesophageal Cancer Working Group: Surgical resection with or without preoperative chemotherapy in oesophageal cancer: A randomised controlled trial. Lancet 359:1727-1733, 2002
12. Urba SG, Orringer MB, Turrisi A, et al: Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol 19:305-313, 2001
13. Walsh TN, Noonan N, Hollywood D, et al: A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 335:462-467, 1996
14. Bosset JF, Gignoux M, Triboulet JP, et al: Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med 337:161-167, 1997
15. Walsh TN, Grennell M, Mansoor S, et al: Neoadjuvant treatment of advanced stage esophageal adenocarcinoma increases survival. Dis Esophagus 15:121-124, 2002
16. Cooper JS, Guo MD, Herskovic A, et al: Chemoradiotherapy of locally advanced esophageal cancer: Long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA 281:1623-1627, 1999
17. Khushalani NI, Leichman CG, Proulx G, et al: Oxaliplatin in combination with protracted-infusion fluorouracil and radiation: Report of a clinical trial for patients with esophageal cancer. J Clin Oncol 20:2844-2850, 2002
18. Fuchs CS, Mayer RJ: Gastric carcinoma. N Engl J Med 333:32-41, 1995
19. Hundahl SA, Phillips JL, Menck HR: The National Cancer Data Base Report on poor survival of U.S. gastric carcinoma patients treated with gastrectomy. Cancer 88:921-932, 1998
20. Gunderson LL, Sosin H: Adenocarcinoma of the stomach: Areas of failure in a re-operation series (second of symptomatic look) clinicopathologic correlation and implications for adjuvant therapy. Int J Radiat Oncol Biol Phys 8:1-11, 1982
21. Murad AM, Santiago FF, Petroianu A, et al: Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 72:37-41, 1993
22. Meyerhardt JA, Fuchs CS: Chemotherapy options for gastric cancer. Semin Radiat Oncol 12:176-186, 2002
23. Fuchs CS: Chemotherapy for advanced gastric cancer: Where do we stand? J Clin Oncol 15:3299-3300, 1997
24. Vanhoefer U, Rougier P, Wilke H, et al: Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol 18:2648-2657, 2000
25. Cersosimo RJ, Hong WK: Epirubicin: A review of the pharmacology, clinical activity, and adverse effects of an adriamycin analogue. J Clin Oncol 4:425-439, 1986
26. Findlay M, Cunningham D, Norman A: A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF). Ann Oncol 5:609-616, 1994
27. Louvet C, Andre T, Tigaud JM, et al: Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients. J Clin Oncol 20:4543-4548, 2002
28. Ilson DH, Minsky B, Kelsen D: Irinotecan, cisplatin, and radiation in esophageal cancer. Oncology (Huntingt) 16:11-15, 2002
29. Ajani JA: Docetaxel for gastric and esophageal carcinomas. Oncology (Huntingt) 16:89-96, 2002
30. Ajani JA, Baker J, Pisters PW, et al: CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma: Results of a phase II study. Cancer 94:641-646, 2002
31. Burris HA III, Moore MJ, Andersen J, et al: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 15:2403-2413, 1997
32. Tempero M, Plunkett W, Ruiz van Haperen V, et al: Randomized phase II trial of dose intense gemcitabine by standard infusion vs. fixed dose rate infusion in metastatic pancreatic adenocarcinoma. Proc Am Soc Clin Oncol 18:273a, 1999 (abstr 1048)
33. Colucci G, Giuliani F, Gebbia V, et al: Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: A prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale. Cancer 94:902-910, 2002
34. Raymond E, Faivre S, Chaney S, et al: Cellular and molecular pharmacology of oxaliplatin. Mol Cancer Ther 1:227-235, 2002
35. Louvet C, Andre T, Lledo G, et al: Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: Final results of a GERCOR multicenter phase II study. J Clin Oncol 20:1512-1518, 2002
36. Rougier P, Ducreux M, Ould Kaci M, et al: Randomized phase II study of oxaliplatin alone (OXA), 5-fluorouracil (5FU) alone, and the two drugs combined (OXA-FU) in advanced or metastatic pancreatic adenocarcinoma (APC). Proc Am Soc Clin Oncol 19:262a, 2000 (abstr 1018)